ATE329619T1 - Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden - Google Patents
Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschädenInfo
- Publication number
- ATE329619T1 ATE329619T1 AT99970328T AT99970328T ATE329619T1 AT E329619 T1 ATE329619 T1 AT E329619T1 AT 99970328 T AT99970328 T AT 99970328T AT 99970328 T AT99970328 T AT 99970328T AT E329619 T1 ATE329619 T1 AT E329619T1
- Authority
- AT
- Austria
- Prior art keywords
- reperfusion injury
- treatment
- ischemic reperfusion
- spla2 inhibitors
- spla2
- Prior art date
Links
- 206010063837 Reperfusion injury Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000000302 ischemic effect Effects 0.000 title 1
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 abstract 1
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heat Treatment Of Articles (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Percussion Or Vibration Massage (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29242398 | 1998-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE329619T1 true ATE329619T1 (de) | 2006-07-15 |
Family
ID=17781604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99970328T ATE329619T1 (de) | 1998-10-14 | 1999-10-07 | Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7098237B1 (de) |
| EP (1) | EP1157704B1 (de) |
| AT (1) | ATE329619T1 (de) |
| AU (1) | AU6004799A (de) |
| CA (1) | CA2346334A1 (de) |
| DE (1) | DE69931963D1 (de) |
| WO (1) | WO2000021563A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787545B1 (en) | 1999-08-23 | 2004-09-07 | Shiongi & Co., Ltd. | Pyrrolotriazine derivatives having spla2-inhibitory activities |
| AU2001267823A1 (en) * | 2000-06-29 | 2002-01-08 | Shionogi And Co., Ltd. | Compounds exhibiting x-type spla2 inhibiting effect |
| TWI314457B (de) * | 2001-03-19 | 2009-09-11 | Shionogi & Co | |
| CA2460347A1 (en) | 2001-09-13 | 2003-03-20 | Synta Pharmaceuticals Corp. | 3-glyoxlylamideindoles for treating cancer |
| IL160810A0 (en) | 2001-09-13 | 2004-08-31 | Synta Pharmaceuticals Corp | 1-glyoxlylamide indolizines for treating cancer |
| PL219736B1 (pl) * | 2002-04-23 | 2015-07-31 | Bristol Myers Squibb Co | Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie |
| US20060030620A1 (en) * | 2004-08-04 | 2006-02-09 | Chia-Yu Chang | Method for treating and/or preventing ischemia/reperfusion injury |
| EP1948602A2 (de) * | 2005-11-03 | 2008-07-30 | Ilypsa, Inc. | Indolverbindungen mit c4-amid-substituenten und ihre verwendung als phospholipase-a2-hemmer |
| US8048880B2 (en) * | 2007-05-03 | 2011-11-01 | Anthera Pharmaceuticals, Inc. | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies |
| CN102325449A (zh) * | 2008-12-19 | 2012-01-18 | 安塞拉制药有限公司 | 用分泌磷脂酶A2(sPLA2)抑制剂或sPLA2抑制剂组合疗法处理主要不良心血管事件和急性冠状动脉综合症的方法 |
| CN107233337A (zh) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| WO2012027579A1 (en) * | 2010-08-26 | 2012-03-01 | Concert Pharmaceuticals, Inc. | Synthetic triterpenoid derivatives |
| AU2018260927B1 (en) * | 2018-05-25 | 2019-02-21 | Graham Sherard Baldwin | Methods and compositions for inhibiting a noxious insult |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| JPH07285866A (ja) | 1994-02-22 | 1995-10-31 | Eisai Co Ltd | 臓器障害予防・治療・改善剤 |
| EP1950200B1 (de) * | 1994-04-01 | 2012-01-11 | Eli Lilly And Company | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]essigsäure methyl ester als sPLA2 inhibitor |
| US6645976B1 (en) | 1994-07-21 | 2003-11-11 | Eli Lilly And Company | Indolizine SPLA2inhibitors |
| US6214876B1 (en) | 1994-07-21 | 2001-04-10 | Eli Lilly And Company | Indene-1-acetamide sPLA2 inhibitors |
| US5641800A (en) * | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| US5648331A (en) * | 1994-08-26 | 1997-07-15 | G.D. Searle & Co. | Method of inhibiting tissue ischemia and reperfusion injury |
| US5733916A (en) * | 1995-03-24 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
| IL124871A (en) | 1995-12-13 | 2002-04-21 | Lilly Co Eli | Naphthyl glyoxamides and medicinal preparations containing them, as inhibitors of sPLA2 |
| DE69614232T2 (de) | 1995-12-13 | 2002-01-10 | Eli Lilly And Co., Indianapolis | Naphthyl-Acetamide als sPLA2-Inhibitoren |
| KR20000049210A (ko) | 1996-10-30 | 2000-07-25 | 피터 지. 스트링거 | 치환된 트리시클릭류 |
| US5916922A (en) * | 1996-12-03 | 1999-06-29 | Eli Lilly And Company | Phenyl glyoxamides as SPLA2 inhibitors |
| US6353128B1 (en) | 1996-12-03 | 2002-03-05 | Eli Lilly And Company | Phenyl acetamides as sPLA2 inhibitors |
| US5747590A (en) * | 1996-12-04 | 1998-05-05 | E. I. Du Pont De Nemours And Company | Acrylic-melamine-functionalized oligomer coating composition |
| ID18983A (id) | 1996-12-04 | 1998-05-28 | Lilly Co Eli | Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia |
| US5919774A (en) | 1996-12-10 | 1999-07-06 | Eli Lilly And Company | Pyrroles as sPLA2 inhibitors |
| WO1998047507A1 (en) * | 1997-04-24 | 1998-10-29 | Shionogi & Co., Ltd. | Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds |
| TW455581B (en) * | 1997-06-26 | 2001-09-21 | Lilly Co Eli | Process for preparing 4-substituted-1H-indole-3-glyoxamides |
| US6610728B2 (en) * | 1997-08-28 | 2003-08-26 | Eli Lilly And Company | Method for treatment of non-rheumatoid arthritis |
| BR9909345A (pt) | 1998-03-31 | 2000-12-12 | Shionogi & Co | Pirrolo [1,2-a] pirazina inibidor de spla2 |
| KR20010034881A (ko) | 1998-05-21 | 2001-04-25 | 시오노 요시히코 | ｓＰＬＡ2 억제 효과를 갖는 피롤로[1,2-ｂ]피리다진 유도체 |
-
1999
- 1999-10-07 DE DE69931963T patent/DE69931963D1/de not_active Expired - Lifetime
- 1999-10-07 AU AU60047/99A patent/AU6004799A/en not_active Abandoned
- 1999-10-07 WO PCT/JP1999/005528 patent/WO2000021563A1/ja not_active Ceased
- 1999-10-07 CA CA002346334A patent/CA2346334A1/en not_active Abandoned
- 1999-10-07 AT AT99970328T patent/ATE329619T1/de not_active IP Right Cessation
- 1999-10-07 EP EP99970328A patent/EP1157704B1/de not_active Expired - Lifetime
- 1999-10-07 US US09/807,603 patent/US7098237B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000021563A1 (en) | 2000-04-20 |
| DE69931963D1 (de) | 2006-07-27 |
| AU6004799A (en) | 2000-05-01 |
| EP1157704A1 (de) | 2001-11-28 |
| CA2346334A1 (en) | 2000-04-20 |
| EP1157704A4 (de) | 2004-02-25 |
| US7098237B1 (en) | 2006-08-29 |
| EP1157704B1 (de) | 2006-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69910368D1 (de) | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen | |
| DE69931963D1 (de) | Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden | |
| DE60011570D1 (de) | Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen | |
| DK1273299T3 (da) | Minoxidilinindeholdende praparater | |
| BR0113161A (pt) | Arilóxi piperidinas não imidazóis | |
| ATE254458T1 (de) | Antibiotische zusammensetzungen zur behandlung des auges | |
| DE69935345D1 (de) | Methoden und zusammensetzungen zur prävention und behandlung der anämie | |
| NO20005237D0 (no) | Heterocyklisk substituerte amider anvendt som calpain- inhibitorer | |
| ATE271385T1 (de) | Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia | |
| ES2191840T3 (es) | Nuevos derivados de aminoacidos y su utilizacion como inhibidores de trombina. | |
| DE60013266D1 (de) | Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion | |
| NO20003018D0 (no) | Triazinangiogenese-inhibitorer | |
| DE60009665D1 (de) | Zusammensetzungen zur behandlung von entzündungsreaktionen | |
| DE60029242D1 (de) | Arzneien zur begleitenden behandlung von glaukomen | |
| FI935780A7 (fi) | HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten | |
| ATE288303T1 (de) | Östrogen agonist-antagonist und testosteron enthaltende zusammensetzung zur behandlung abnehmender testosteronspiegel | |
| FI935779L (fi) | HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten | |
| ATE428425T1 (de) | Spla2-inhibitoren zur behandlung von arteriosklerose | |
| ATE332688T1 (de) | Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung | |
| ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| ES2096874T3 (es) | Inhibidor de la proteasa de hiv util para el tratamiento del sida. | |
| ATE263566T1 (de) | Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom | |
| DE60203026D1 (de) | Sulfonylpyridazinone Derivate zur Behandlung von ischämischem Gewebeschaden | |
| WO2003041640A3 (en) | METHODS FOR TREATING ISCHEMIC REPERFUSION INJURY USING IkB KINASE-BETA INHIBITORS | |
| DE60000658D1 (de) | Zusammensetzung zur behandlung von psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |